Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients. Issue 5 (29th April 2022)

• Record Type: Journal Article
• Authors: Chevallier, Patrice; Jullien, Maxime; Peterlin, Pierre; Garnier, Alice; Le Bourgeois, Amandine; Coste‐Burel, Marianne; Béné, Marie C.; Guillaume, Thierry
• Is Part Of: Hematological oncology. Volume 40:Issue 5(2022)
• Page Start: 1097
• Page End: 1099
• Publication Date: 2022-04-29
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.3006
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstrate a long‐term high protection of Allo‐HSCT recipients since only 2 infections and one death related to COVID‐19 occurred.